KRAS and urinary bladder cancer: For other novel nonsynonymous mutations, 57 mutations occurred in Cancer Gene Census genes or other genes known to be recurrently mutated in bladder cancer genes [6, 36, 37], including 10 predicted loss-of-function mutations (BLCAb001: MLL2 Q1361*, ARID2 L47fs; BLCAb002: ZFP36L1 F253fs, MYST4 E1398fs, MLL S2663*, KRAS E3_splice, KDM6A Q958*, ETV4 Q170*, ELF3 D223fs, BMPR1A R361*).